Healthcare Ecosystem
Pharma, biotech, devices, managed care, and tools — structurally growing spend with patent, reimbursement, and pipeline risk.
Covered market cap
Ecosystem map
Click a group to open its subsector notes.
Therapeutics
Devices
Payers
Enablers
Pharmaceuticals
TherapeuticsLarge-cap drug franchises with GLP-1, oncology, vaccines, and diversified pipelines.
Drivers
- New-product launches and volume
- Patent life and pricing
- International reimbursement
Key risks
- Patent cliffs and biosimilars
- IRA / drug-price negotiation
- Clinical and safety setbacks
Biotech
TherapeuticsInnovation platforms with higher pipeline optionality and binary trial risk.
Drivers
- Clinical readouts
- Specialty-drug demand
- M&A from large pharma
Key risks
- Trial failures
- Payer pushback on high-cost therapies
- Equity-market funding windows
Medical Devices
DevicesProcedure-driven hardware with hospital capex and surgeon preference.
Drivers
- Elective procedure volumes
- New-platform share gains
- Emerging-market hospital build-out
Key risks
- Hospital budget pressure
- Product recalls and litigation
- Reimbursement cuts
Managed Care
PayersRisk-bearing insurers spanning commercial, Medicare Advantage, and Medicaid.
Drivers
- Membership mix (MA vs commercial)
- Medical loss ratio
- Rate notices and Star ratings
Key risks
- Utilization spikes
- CMS rate cuts
- Regulatory and political scrutiny
Companies
Market cap, P/E, and EV/EBITDA come from cached fundamentals when present. Price is not fetched on this page.
| Ticker | Name | Market cap | Price | P/E | EV/EBITDA |
|---|---|---|---|---|---|
| LLY.US | Eli Lilly and Company | 1140.2B | — | 42.8x | — |
| MRK.US | Merck & Company Inc | 346.9B | — | 113.4x | — |
| PFE.US | Pfizer Inc | 169.8B | — | 39.2x | — |
| JNJ.US | Johnson & Johnson | 646.9B | — | 40.8x | — |
| VRTX.US | — | — | — | — | — |
| AMGN.US | — | — | — | — | — |
| GILD.US | Gilead Sciences Inc | 196.8B | — | — | — |
| ABT.US | Abbott Laboratories | 180.6B | — | 38.6x | — |
| MDT.US | — | — | — | — | — |
| SYK.US | Stryker Corporation | 115.6B | — | 31.2x | — |
| UNH.US | UnitedHealth Group Incorporated | 368.6B | — | 26.4x | — |
| ELV.US | Elevance Health Inc | 93.5B | — | 18.3x | — |
| TMO.US | Thermo Fisher Scientific Inc | 253.2B | — | 36.1x | — |
| ISRG.US | Intuitive Surgical Inc | 159.6B | — | 54.6x | — |
Valuation framework
Starting methods by business type — refine as you add coverage.
DCF
UNH.US, TMO.US, ISRG.US
EV/EBITDA
JNJ.US, ABT.US, AMGN.US
SOTP
LLY.US, JNJ.US
Scenarios
Directional cases for the sector — not stock-level price targets.
Pipeline wins plus utilization cooling at payers; tools restock as biotech funding returns.
Procedure volumes normalize, MA rate pressure digestible, GLP-1 and oncology sustain growth.
Drug-price reform bites, MA losses widen, and a procedure recession hits devices.